HRP20030833B1 - Liquid pharmaceutical composition - Google Patents

Liquid pharmaceutical composition

Info

Publication number
HRP20030833B1
HRP20030833B1 HR20030833A HRP20030833A HRP20030833B1 HR P20030833 B1 HRP20030833 B1 HR P20030833B1 HR 20030833 A HR20030833 A HR 20030833A HR P20030833 A HRP20030833 A HR P20030833A HR P20030833 B1 HRP20030833 B1 HR P20030833B1
Authority
HR
Croatia
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
composition
polyhydric alcohols
volume
Prior art date
Application number
HR20030833A
Other languages
English (en)
Croatian (hr)
Inventor
Mahesh Kulkarni Neema
Schneider Michael
Bernard Silbering Steven
Richard Meyer-Wonnay Hans
Sanii-Yahyai Nahid
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030833(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of HRP20030833A2 publication Critical patent/HRP20030833A2/hr
Publication of HRP20030833B1 publication Critical patent/HRP20030833B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
HR20030833A 2001-05-25 2002-04-29 Liquid pharmaceutical composition HRP20030833B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29383201P 2001-05-25 2001-05-25
US34373301P 2001-10-25 2001-10-25
PCT/IB2002/001500 WO2002094220A1 (en) 2001-05-25 2002-04-29 Liquid pharmaceutical composition

Publications (2)

Publication Number Publication Date
HRP20030833A2 HRP20030833A2 (en) 2004-08-31
HRP20030833B1 true HRP20030833B1 (en) 2007-04-30

Family

ID=26968180

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030833A HRP20030833B1 (en) 2001-05-25 2002-04-29 Liquid pharmaceutical composition

Country Status (43)

Country Link
US (2) US20020198261A1 (de)
EP (1) EP1395242B1 (de)
JP (1) JP2004534764A (de)
KR (1) KR100582963B1 (de)
CN (1) CN100346779C (de)
AP (1) AP1815A (de)
AR (1) AR033922A1 (de)
AT (1) ATE334656T1 (de)
AU (1) AU2002258026B2 (de)
BG (1) BG108376A (de)
BR (1) BR0209973A (de)
CA (1) CA2446574C (de)
CR (1) CR7150A (de)
CY (1) CY1105147T1 (de)
CZ (1) CZ299755B6 (de)
DE (1) DE60213592T2 (de)
DK (1) DK1395242T3 (de)
DO (1) DOP2002000403A (de)
EA (1) EA008087B1 (de)
EE (1) EE200300587A (de)
EG (1) EG24078A (de)
ES (1) ES2265040T3 (de)
GE (1) GEP20053620B (de)
HR (1) HRP20030833B1 (de)
HU (1) HUP0401366A2 (de)
IL (1) IL158359A0 (de)
IS (1) IS2428B (de)
MA (1) MA27026A1 (de)
MX (1) MXPA03009392A (de)
MY (1) MY128615A (de)
NO (1) NO20035200L (de)
NZ (1) NZ529173A (de)
OA (1) OA12604A (de)
PA (1) PA8545901A1 (de)
PE (1) PE20030087A1 (de)
PL (1) PL366384A1 (de)
PT (1) PT1395242E (de)
RS (1) RS87203A (de)
SI (1) SI1395242T1 (de)
SK (1) SK286227B6 (de)
SV (1) SV2003001053A (de)
WO (1) WO2002094220A1 (de)
ZA (1) ZA200308393B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3693258B2 (ja) 1996-07-24 2005-09-07 ワーナー―ランバート・コンパニー イソブチルｇａｂａまたはその誘導体を含有する鎮静剤
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2004016260A1 (en) * 2002-08-15 2004-02-26 Pfizer Limited Therapeutic use of fused bicyclic or tricyclic amino acids
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
JP2006513257A (ja) * 2002-12-13 2006-04-20 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 線維筋痛症および他の障害を処置するためのプレガバリン誘導体
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
AU2004271800A1 (en) * 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
CN1867359B (zh) * 2003-10-08 2010-12-15 马林克罗特公司 哌甲酯溶液及其制药用途和制备方法
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
EP1543831A1 (de) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Zusammensetzung enthaltend Pregabalin
DE102004015752B4 (de) * 2004-03-31 2007-04-05 Christian-Albrechts-Universität Zu Kiel Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen
KR100870381B1 (ko) * 2004-10-14 2008-11-25 다이킨 고교 가부시키가이샤 분위기개변방법, 그리고 이에 이용되는 분무제 및 분무장치
US20100168070A1 (en) * 2005-08-11 2010-07-01 Niklas Heine Compounds for the treatment of alzheimer's disease
EP1919861A2 (de) * 2005-08-11 2008-05-14 Boehringer Ingelheim International GmbH Verbindungen zur behandlung der alzheimer erkrankung
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2246044A1 (de) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Kinderärztliche Lösungen für Betablocker
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2923694B1 (de) * 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Orale flüssige pharmazeutische lösung von gabapentin
CN104940930A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫药物口服乳剂及其制备方法
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
CN112566625A (zh) 2018-08-18 2021-03-26 夫特弗制药私人有限公司 口服剂量的化学治疗药物悬浮液
WO2020039263A2 (en) * 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
CA3131336A1 (en) * 2019-03-26 2020-10-01 Mirja Huhtinen Pregabalin formulations and use thereof
KR20230147067A (ko) 2021-01-22 2023-10-20 에지스 지오기스제르기아르 지알티 분산된 프레가발린을 함유하는 국소 제형
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
US20240099989A1 (en) * 2021-02-05 2024-03-28 Kinki University Agent for preventing or improving peripheral neuropathy
EP4395758A4 (de) * 2021-08-31 2025-07-30 Avion Pharmaceuticals Llc Stabiles gabapentinpulver

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
EP1077692B1 (de) * 1998-05-15 2004-07-28 Warner-Lambert Company LLC Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung
WO2002043762A2 (en) * 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
CN100346779C (zh) 2007-11-07
AP1815A (en) 2008-01-04
CN1509165A (zh) 2004-06-30
CZ20033066A3 (cs) 2004-08-18
ZA200308393B (en) 2005-04-26
DOP2002000403A (es) 2002-11-30
EA008087B1 (ru) 2007-02-27
RS87203A (sr) 2006-10-27
EE200300587A (et) 2004-02-16
CZ299755B6 (cs) 2008-11-12
HK1062646A1 (zh) 2004-11-19
PL366384A1 (en) 2005-01-24
PE20030087A1 (es) 2003-02-14
ATE334656T1 (de) 2006-08-15
KR20040003006A (ko) 2004-01-07
MA27026A1 (fr) 2004-12-20
MXPA03009392A (es) 2004-01-29
PT1395242E (pt) 2006-11-30
DK1395242T3 (da) 2006-10-30
NO20035200D0 (no) 2003-11-24
IL158359A0 (en) 2004-05-12
BR0209973A (pt) 2004-04-06
KR100582963B1 (ko) 2006-05-24
HRP20030833A2 (en) 2004-08-31
EA200301152A1 (ru) 2004-04-29
CA2446574A1 (en) 2002-11-28
DE60213592D1 (de) 2006-09-14
PA8545901A1 (es) 2003-09-05
EG24078A (en) 2008-05-11
DE60213592T2 (de) 2007-08-09
GEP20053620B (en) 2005-09-26
CY1105147T1 (el) 2010-03-03
SK286227B6 (sk) 2008-05-06
AR033922A1 (es) 2004-01-07
CR7150A (es) 2004-02-23
US20020198261A1 (en) 2002-12-26
ES2265040T3 (es) 2007-02-01
WO2002094220A1 (en) 2002-11-28
AU2002258026B2 (en) 2007-08-02
SK14112003A3 (sk) 2004-08-03
US7256216B2 (en) 2007-08-14
NZ529173A (en) 2005-07-29
NO20035200L (no) 2003-11-24
CA2446574C (en) 2008-04-01
HUP0401366A2 (hu) 2004-11-29
EP1395242B1 (de) 2006-08-02
IS2428B (is) 2008-10-15
JP2004534764A (ja) 2004-11-18
IS6986A (is) 2003-10-09
OA12604A (en) 2006-06-08
SI1395242T1 (en) 2006-10-31
MY128615A (en) 2007-02-28
AP2003002907A0 (en) 2003-12-31
BG108376A (bg) 2005-04-30
EP1395242A1 (de) 2004-03-10
US20040072904A1 (en) 2004-04-15
SV2003001053A (es) 2003-03-18

Similar Documents

Publication Publication Date Title
HRP20030833B1 (en) Liquid pharmaceutical composition
DE60014035D1 (de) Zusammensetzung zur hautdesinfektion
EP1649760A4 (de) Zusammensetzung, die equolproduzierende milchsäurebakterien enthält
EP0732930A4 (de) Zusammensetzungen, die die Apoptose inhibitieren, Methode zur Reinigung der Zusammensetzunge und ihre Verwendung
BR0013157A (pt) Composições farmacêuticas e nutricionais contendo ácidos graxos essenciais e agentes de abaixamento da homocisteìna
ATE409512T1 (de) Verbindungen zur kontrollierten freigabe aktiver molekülen
ATE275562T1 (de) Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen
DK1273299T3 (da) Minoxidilinindeholdende praparater
MY133174A (en) Dipeptide nitriles
MEP90508A (en) New pharmaceutical composition
UY27329A1 (es) Champues con alcohol de behenilo
CR8107A (es) Fungicida
ES2193874B1 (es) Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas.
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
HRP20070577T4 (hr) Derivati kinazolinona koji se mogu upotrijebiti kao antagonisti vaniloida
ATE515252T1 (de) Pseudokörpergeruchszusammensetzung
DE60311830D1 (de) Wasserlöslicher behälter
ATE359279T1 (de) Moschus-geruchsstoffe
DE60132441D1 (de) A als inhibitor der no-synthase und verwendungen
PL1553162T3 (pl) Toaletowe kostki
TNSN98013A1 (fr) Derives de 5 - aroylnaphtalene a action anti-inflammatoire et analgesique, compositions pharmaceutiques les contenant, et procedes pour les utiliser et les preparer.
ATE342880T1 (de) Aliphatische verbindungen als duftstoffe mit moschuscharakter
WO2002056840A3 (de) Kosmetisches und/oder pharmazeutisches mittel acylierte aminosaüre enthaltend.
DE60001366D1 (de) Orale zusammensetzung enthaltend perlit
MXPA04005308A (es) Compuestos organicos.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080402

Year of fee payment: 7

PBON Lapse due to non-payment of renewal fee

Effective date: 20090430